The defining feature of Medi-Weightloss is not a medication checkout page. It is a recurring clinic visit. The company describes a physician-led program delivered in person, with weekly appointments during its Acute Weight Loss and Short-Term Maintenance phases and monthly appointments during Wellness. For someone comparing GLP-1 services, that changes the practical question: not simply whether a prescription is available, but who evaluates you, how often you return and how the clinic coordinates medication and follow-up.
Public documentation consulted October 19, 2026, describes brand-name and compounded medication options, a free assessment, a separate $199 self-pay New Patient Visit and locally priced memberships. It also names pharmacy partners without establishing which pharmacy serves each patient or how medication reaches them. This review follows those handoffs, distinguishing the network’s published process from details that still need confirmation at the selected clinic. It does not independently verify clinicians, pharmacy licenses, availability or patient outcomes.
At a glance
- Main care setting
- The provider describes in-person care, weekly visits in its first two phases and monthly visits in Wellness; many locations also offer supporting telehealth.Sources: [10]
- First paid clinical visit
- The self-pay New Patient Visit is advertised at $199, including medical assessment, laboratory work and GLP-1 eligibility review. It follows a free assessment.
- Medication charges
- Medication costs are separate from program fees. Compounded semaglutide starts at $99 for the first month and compounded tirzepatide at $199 for the first month; later prices are not established.Sources: [12]
- Prescribing and sourcing
- Prescriptions require medical evaluation and approval. For compounded options, the provider says it sources medication directly from a pharmacy it describes as licensed.
- Local availability
- The locator advertises 139 locations, but medication availability and eligibility are confirmed at the New Patient Visit, not guaranteed across the network.Sources: [6]
Start with the clinic, not just the brand
Medi-Weightloss advertises a national clinic network rather than a single remote prescribing service. Its locator reports 139 locations and supports ZIP-code searches; other program pages use the broader description “130+.” Those counts describe the advertised network, not confirmed access to every treatment in every state. The locator also contains inconsistent address blocks, so confirming the actual clinic address and appointment location is more useful than treating every listing as independently verified.
The corporate structure matters to the care journey. Website terms describe businesses and area managers operating as separate legal entities under franchise or fractional-franchise agreements, not as the company’s agents or employees. That does not identify the clinical contracting entity at an individual location. Before enrollment, ask which entity provides care, which clinician will evaluate you and who handles billing, records and medication questions if more than one organization is involved.
Booking ahead is recommended. Some clinics may have same-day appointments, while others book farther out; no uniform appointment or clinical-review turnaround is published. Online booking is available through local clinics. The contact form offers a Spanish-language communication preference, but that does not confirm fully Spanish-language clinical care everywhere. These are local access questions, especially when recurring in-person appointments must fit around work, transportation or caregiving.
The free assessment and medical work-up are different steps
The published entry sequence begins with a free assessment, followed by a New Patient Visit. For self-pay patients, that second step is advertised at $199 and includes medical assessment, lab work and a GLP-1 eligibility review. The free assessment therefore should not be understood as a free comprehensive medical visit or a promise of medication. The provider says the eventual plan reflects metabolic rate, health profile and personal preferences.
The New Patient Visit typically includes a full medical and health history, blood panel, EKG and body-composition analysis. Recent physical-exam, EKG or blood-work results from a primary care physician may be accepted after the patient signs a release. Bring photo identification, an insurance card if applicable, a medication and supplement list, and recent records. Our first-consultation preparation guide provides a framework for organizing questions alongside those documents.
Medi-Weightloss describes its program as potentially helpful for people with a BMI of 25 or higher, people considering medication and people with certain metabolic conditions. That is a broad program description, not a sufficient criterion for a GLP-1 prescription. Its disclaimer requires evaluation and approval by a licensed provider. The materials also do not establish a standard first-visit duration, so ask how much time to reserve and whether all testing occurs that day.
A medication menu is not a prescribing decision
The network lists Wegovy, Zepbound and Saxenda, identifying their ingredients as semaglutide, tirzepatide and liraglutide, respectively. It also lists Contrave, oral appetite suppressants phentermine and phendimetrazine, and compounded semaglutide and tirzepatide. This is a broader weight-management offering than a GLP-1-only service. The provider explicitly places confirmation of eligibility and specific medication availability at the New Patient Visit rather than guaranteeing a particular product before evaluation.
Its description of care is physician-led, but it says patients meet with licensed medical providers. That language does not establish that every appointment is with a physician. Medication, when included, is prescribed and monitored by a Medi-Weightloss provider rather than determined by a questionnaire alone. Ask who conducts the initial evaluation, who issues prescriptions and who reviews medication concerns between visits; the network-level materials do not identify those professionals for each clinic.
The public pricing descriptions do not establish the formulation, route, presentation or quantity for each compounded offer. An ingredient name is not enough to resolve those details. Our product and formulation checklist can help structure that discussion. NIDDK advises that medication selection consider benefits, side effects, health conditions, other medicines, family history and cost. A provider’s menu cannot substitute for that individualized clinical discussion.
The pharmacy handoff is documented more clearly than delivery
For compounded medication, Medi-Weightloss says its provider determines whether that option is appropriate and sources it directly from a licensed pharmacy on the patient’s behalf. Its published partner list names BPI Labs, Innovation Compounding, EverWell Pharmacy, Nova Specialty Pharmacy, Absolute Pharmacy, Belmar Pharma Solutions, AnazaoHealth and Empower Pharmacy. Listed addresses are in Florida, Georgia and Texas. These are disclosed relationships, not independent verification of licensing or proof that any named pharmacy will fill a particular prescription.
The missing operational details are consequential: the consulted materials do not specify which pharmacy serves each clinic, home delivery versus pickup, shipping charges, carrier, refrigeration arrangements or dispatch and arrival timelines. They also do not establish whether medication is administered at the clinic or supplied for use elsewhere in each plan. The pharmacy-handoff questions are especially relevant here: obtain the dispensing pharmacy’s identity, contact information and written fulfillment instructions before assuming how access will work.
Compounded preparations are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality. FDA recommends using them when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence. If an injectable GLP-1 arrives warm or insufficiently refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy.
| Step | Published process | Confirm locally |
|---|---|---|
| Entry | Free assessment followed by a New Patient Visit | Appointment length and scheduling availability |
| Evaluation | History, testing and GLP-1 eligibility review | Which recent records can replace repeat testing |
| Prescribing | Licensed-provider evaluation and approval required | Prescriber, exact product and presentation |
| Pharmacy | Provider sources compounded options from a pharmacy | Assigned pharmacy, pickup or delivery, and charges |
| Follow-up | Weekly initially, then monthly in Wellness | Between-visit response route and urgent concerns |
Weekly follow-up is the core service
During Acute Weight Loss and Short-Term Maintenance, the advertised schedule is weekly clinic visits. During Wellness, it becomes monthly. The provider says those appointments allow its team to review progress and adjust nutrition, supplements or medication. A typical visit includes body-composition analysis, weight and measurements, discussion of eating and habits, medication side-effect monitoring when applicable, and brief education about portions, lifestyle and behavior. This is a recurring service obligation, not merely prescription renewal.
The wider support package includes in-person nutrition and fitness education, behavioral coaching around emotional eating, stress and sleep, and access to a patient membership website between appointments. Nutrition is described as grocery-store food supplemented by Medi-Weightloss Signature Products, with optional Signature Menus for structured planning. It is not presented as an entirely prepackaged-food diet. Ask which products are expected in your proposed plan and whether they carry charges beyond the membership.
Many locations advertise telehealth to support patients between visits, but the program is not documented as uniformly remote. Nor do the materials publish a standard response time, after-hours arrangement or dedicated medication-problem pathway. The distinction matters when comparing ongoing support models: scheduled monitoring, educational resources and prompt clinical responses are different services. Ask the clinic how to report side effects and who covers messages when the usual clinician is unavailable.
Follow the separate bills through the care pathway
After the $199 self-pay New Patient Visit, Medi-Weightloss advertises one-, three- and six-month program options with prices determined locally. Membership typically includes assessment, weekly in-person visits, body-composition analysis, nutrition plans and education, progress tracking and website access. Follow-up visits are described as built into membership. The documentation does not establish a single national membership price or a total treatment cost, and package duration alone does not establish medication quantity or a minimum commitment.
Medication is priced separately. For patients whose brand-name GLP-1 is not covered, the provider advertises compounded semaglutide starting at $99 for the first month and compounded tirzepatide starting at $199 for the first month. These are introductory medication prices, not all-inclusive program prices or published renewal rates. Later medication charges, quantities, formulations and complete promotional conditions remain unestablished. Repeat labs, supplements, specialized treatments, hormone optimization and IV therapy may also generate separate charges.
The pricing page says most insured patients pay $0–$50 per visit, depending on coverage and deductible status; it does not guarantee that range for an individual. Patients remain responsible for copays, deductibles, coinsurance and noncovered services. Confirm clinic participation, clinician participation, covered services and medication benefits separately. Medi-Weightloss also advertises HSA/FSA eligibility and reimbursement documentation, while directing patients to confirm account rules with their plan administrator rather than treating acceptance as a tax determination.
Check continuity before accepting a payment plan
Medi-Weightloss states that it is not contract-based and does not require advance payment. It also says some locations offer value or loyalty plans that do require prepayment, and it advertises financing whose details are available locally. Those statements describe alternatives, not mandatory upfront collection for everyone. Before choosing one, obtain the actual price, covered visits, medication exclusions, payment dates and the consequences of changing clinics or interrupting participation.
The consulted documentation does not clearly establish clinical-program auto-renewal, cancellation notice requirements, refund rules or how unused prepaid services are treated. A statement that there is no contract does not answer those operational questions, and cancellation does not itself establish a refund entitlement. Ask for written terms covering missed appointments, pauses, medication already ordered and any balance remaining under a financing arrangement. This is particularly important when follow-up frequency changes between program phases.
Communication enrollment has its own terms. The contact form states consent to service-related and marketing SMS and email, warns that message and data rates may apply, and says users can reply STOP to opt out of texts. It lists security@mediweightloss.com for help. That contact is not identified as a clinical advice line. Establish a separate, appropriate route for medical questions rather than assuming replies to promotional or scheduling messages reach the treating team.
Keep additional programs separate from GLP-1 care
The standard Medi-Weightloss program is described as adult-focused, alongside a separate adolescent program for ages 12–18. The latter includes individual and family consultations, nutrition and exercise education, medical evaluation, blood testing, EKG, indirect-calorimetry assessment and a starter kit. Those offerings do not establish medication eligibility for every adolescent. Website terms separately restrict site access and use to legal adults age 18 or older, leaving families a practical reason to ask how parent-managed enrollment works.
The provider describes participation during pregnancy or breastfeeding as case-by-case, coordinated with an OB/GYN or primary care doctor. That is not blanket acceptance or permission to use a particular medication. For adults preparing for consultation, NIDDK recommends discussing medicines, supplements, allergies and pregnancy plans with the clinician. A general program eligibility statement should not be stretched into a medication-specific assurance, particularly when the public materials leave the exact proposed product to the clinical visit.
Many clinics also advertise nutrient injections, including B-vitamin preparations, L-Lean and Muscle Guard Booster; the provider explicitly says these injections are not for weight loss. IV therapy is another advertised service, with a 20% first-infusion promotion but no base price in the consulted excerpt. Its weight-related promotional language is not consistent throughout the materials. Keep these optional services, their charges and their claimed benefits separate from the documented GLP-1 prescribing and monitoring pathway.
Questions & answers
Does the free assessment include the $199 medical visit?
No. The published sequence separates a free assessment from the self-pay New Patient Visit, advertised at $199. That paid visit includes medical assessment, laboratory work and GLP-1 eligibility review. Ask the clinic what happens at each stage, when payment is collected and whether recent outside testing can be accepted. Neither stage guarantees a prescription.
Can I complete Medi-Weightloss entirely through telehealth?
The public materials do not establish an entirely remote pathway across the network. Medi-Weightloss describes in-person care with weekly visits initially and monthly Wellness visits. Many locations offer telehealth as support between appointments. Confirm your selected clinic’s requirements, which encounters can be remote and whether that arrangement changes testing, monitoring or fees before enrolling.
Are the $99 and $199 compounded medication offers ongoing prices?
No ongoing rate is established. The provider advertises compounded semaglutide starting at $99 for the first month and compounded tirzepatide starting at $199 for the first month, separately from program fees. Subsequent prices, supplied quantities, formulation, route and complete promotional conditions need confirmation. Ask for a written breakdown that distinguishes the first month from later treatment.
Which pharmacy will supply my compounded medication?
The network publishes several pharmacy partners and says the provider sources compounded medication on the patient’s behalf. It does not assign a specific pharmacy to each patient in the consulted documentation. Ask for the dispensing pharmacy’s name, direct contact details, exact product information and fulfillment arrangements. The partner list alone does not confirm licensing, delivery timing or your prescription’s destination.
Does insurance acceptance mean my GLP-1 will be covered?
No. The provider says coverage is not guaranteed and that patients remain responsible for applicable cost-sharing and noncovered services. Its $0–$50 per-visit statement is conditional, not an individual quote. NIDDK likewise distinguishes medication coverage between insurance plans. Confirm benefits for the consultation, tests, follow-up and exact medication separately rather than assuming one coverage decision answers all four.
Will I have to prepay, and can I get unused money back?
Medi-Weightloss says advance payment is not generally required, although some local value or loyalty plans require it. Financing may also be available. The consulted materials do not establish refund rights for unused prepaid services or detailed cancellation rules. Obtain those terms before choosing an optional prepaid plan; the general statement that the program is not contract-based does not resolve refunds.
Our assessment
Medi-Weightloss documents a comparatively tangible care structure: an initial medical work-up, recurring in-person monitoring, nutrition and behavioral support, and provider-managed sourcing for compounded options. That structure may appeal to adults who want regular clinic contact rather than a primarily online transaction. Its practical value, however, depends on the selected location. Before paying, obtain the local clinician and contracting entity, an itemized ongoing price, the exact medication and pharmacy, fulfillment arrangements, between-visit contact instructions and written cancellation terms. The public documentation explains the clinic routine more clearly than it explains medication delivery or the full financial commitment; it does not establish provider-specific treatment outcomes.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Medi-Weightloss® — terms of use ↗
- Medi-Weightloss® — weight loss programs/adolescent program ↗
- Medi-Weightloss® — weight loss programs/vitamin nutrition injections ↗
- Medi-Weightloss® — weight loss clinic ↗
- Medi-Weightloss® — get started ↗
- Medi-Weightloss® — weight loss programs/iv therapy for weight loss ↗
- Medi-Weightloss® — about us/faq ↗
- Medi-Weightloss® — weight loss programs/medi weightloss program ↗
- Medi-Weightloss® — official website ↗
- Medi-Weightloss® — pricing ↗